A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 15 Jun 2018 Results (n=104) published in the Journal of Clinical Oncology.
- 10 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Status changed from active, no longer recruiting to completed.